To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

Clinical trial NCT02624492 · COMPLETED

Trial details

NCT number: NCT02624492
Sponsor: Boehringer Ingelheim
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma, Large B-Cell, Diffuse

Start date: 2016-01-28
Primary completion: 2018-03-16
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.